Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX), Has a "More Favorable View of the Company"
Tweet Send to a Friend
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $7.00 price target on VolitionRX (NYSE: VNRX), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
